



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/090,624	03/06/2002	Hikaru Takakura	TAKAKURA=6A	5382
1444	7590	01/14/2004	EXAMINER	
BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, NW SUITE 300 WASHINGTON, DC 20001-5303			FRONDA, CHRISTIAN L	
			ART UNIT	PAPER NUMBER
			1652	

DATE MAILED: 01/14/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

10/090,624

Applicant(s)

TAKAKURA ET AL.

Examiner

Christian L Fronda

Art Unit

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-19 is/are pending in the application.
- 4a) Of the above claim(s) 6-19 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-5 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 06 March 2002 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. §§ 119 and 120

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☒ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☒ Certified copies of the priority documents have been received in Application No. 09/445,472.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.  
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 3/6/02, 2/3/03, 6/3/03
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_

Art Unit: 1652

## DETAILED ACTION

### *Election/Restriction*

1. Applicants' election with traverse of Group I, claims 1-5 and SEQ ID NO: 1, is acknowledged. The traversal is on the grounds that Groups I and II are not two distinct inventions and that there is no burden to search more than one amino acid sequence. This is not found persuasive for reasons of record as supplemented below.

The inventions of Groups I and II are independent chemical entities since each of their respective amino acid sequences and nucleotide sequences encoding are different which requires different searches to be completed. Furthermore, PRO represents any protein to be expressed as defined in claim 6. A search of all the amino acid and/or nucleotide sequences in the patent literature and the non-patent literature cannot be made without serious burden because the sequences require separate searches that have different limits, boundaries, scope, and subject matter. Upon further reconsideration, SEQ ID NO: 2 will also be searched.

The requirement is still deemed proper and is therefore made FINAL.

2. Claims 1-5, SEQ ID NO: 1, and SEQ ID NO:2 are under consideration in this Office Action.

### *Claim Objections*

3. Claim 1 is objected to because claim 1 recites nonelected subject matter of SEQ ID NO:
4. Applicant is required to cancel the claim or amend the claim to recite the elected subject matter of SEQ ID NO: 1.

### *Claim Rejections - 35 U.S.C. § 101*

4. 35 U.S.C. 101 reads as follows:  
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
5. Claims 1-5 are rejected under 35 USC 101 because the claimed invention is directed to

Art Unit: 1652

non-statutory subject matter.

Claims 1-5, as written, do not sufficiently distinguish over nucleic acids, proteins, cells and antibodies as they exist naturally because the claims do not particularly point out any non-naturally occurring differences between the claimed products and the naturally occurring products. In the absence of the hand of man, the naturally occurring products are considered non-statutory subject matter. *See Diamond v. Chakrabarty*, 447 U.S. 303, 206 USPQ 193 (1980). The claims should be amended to indicate the hand of the inventor, e.g., by insertion of "Isolated polynucleotide" or "Purified polynucleotide". See MPEP 2105.

***Claim Rejections - 35 U.S.C. § 112, 1st Paragraph***

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 1-5 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claimed invention encompass any protease gene comprising as yet to be discovered promoter(s), regulatory element(s), and untranslated regions; and a polynucleotide encoding SEQ ID NO: 1, a polynucleotide of SEQ ID NO: 2, or a polynucleotide encoding a protease consisting of an amino acid sequence in which one or more amino acid residues are deleted, substituted, inserted, or added to the amino acid sequence of SEQ ID NO: 1

The specification, however, only provides the a written description of a polynucleotide of SEQ ID NO: 2 and a polynucleotide encoding SEQ ID NO: 1. The specification does not provide a written description of yet to be discovered promoter(s), regulatory element(s), and untranslated regions as encompassed by the claimed protease gene. Applicants have failed to sufficiently describe the claimed invention, in such full, clear, concise, and exact terms that a skilled artisan would recognize Applicants were in possession of the claimed invention.

8. Claim 5 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or an isolated polynucleotide comprising SEQ ID NO: 1; does not

Art Unit: 1652

reasonably provide enablement for any other embodiment.

Factors to be considered in determining whether undue experimentation is required, are summarized In re Wands [858 F.2d 731, 8 USPQ 2nd 1400 (Fed. Cir. 1988)]. The Wands factors are: (a) the quantity of experimentation necessary, (b) the amount of direction or guidance presented, (c) the presence or absence of working example, (d) the nature of the invention, (e) the state of the prior art, (f) the relative skill of those in the art, (g) the predictability or unpredictability of the art, and (h) the breadth of the claim.

The nature and breadth of the claim encompass any protease gene encoding any protein consisting of an amino acid sequence in which one or more amino acid residues are deleted, substituted, inserted, or added to the amino acid sequence of SEQ ID NO: 1.

The specification provides guidance and examples for making. However, the specification does not teach the specific structural/catalytic amino acids and the structural motifs essential for protein activity/function which cannot be altered. The state of the art as exemplified by Attwood et al. (Comput. Chem. 2001, Vol. 25(4), pp. 329-39) is such that "...we do not fully understand the rules of protein folding, so we cannot predict protein structure; and we cannot invariably diagnose protein function, given knowledge only of its sequence or structure in isolation" (see Abstract and entire publication). Furthermore, Ponting (Brief. Bioinform. March 2001, Vol. 2(1), pp. 19-29) states that "...predicting function by homology is a qualitative, rather than quantitative, process and requires particular care to be taken...due attention should be paid to all available clues to function, including orthologue identification, conservation of particular residue types, and the co-occurrence of domains in proteins" (See Abstract and entire publication).

The standard for meeting the enablement requirement is whether one of skill in the art can make the invention without undue experimentation. The amount of experimentation to make the claimed polynucleotide is enormous and entails selecting specific nucleotides to change (deletion, insertion, substitution, addition, or combinations thereof) in a polynucleotide to make the claimed polynucleotide and determining by assays whether the polypeptide has protease activity. The specification does not provide guidance with respect to the specific structural/catalytic amino acids and the structural motifs essential for enzyme structure and activity/function which must be preserved. Thus, searching for the specific nucleotides to change (deletion, insertion, substitution, addition, or combinations thereof) in a polynucleotide to make the claimed polynucleotide is well outside the realm of routine experimentation and predictability in the art of success in determining whether the resulting polypeptide has protease activity is extremely low since no information is provided by the specification regarding the specific catalytic amino acids and the structural motifs essential for enzyme structure and activity/function which must be preserved.

The Examiner finds that one skilled in the art would require additional guidance, such as information regarding the specific catalytic amino acids and the structural motifs essential for

Art Unit: 1652

activity/function which must be preserved. Without such a guidance, the experimentation left to those skilled in the art is undue.

***Claim Rejections - 35 U.S.C. § 112, 2nd Paragraph***

9. The following is a quotation of the second paragraph of 35 U.S.C. 112:  
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
10. Claims 1-5 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.  
Claims 1-5 are vague and indefinite because the meaning of the phrase "thermostable protease activity" is not known and not recited in the claims.  
Claim 3 is vague and indefinite because the meaning of the phrase "base sequence" is not known. Amending the claim to recite the phrase "nucleotide sequence" may overcome this rejection.  
Claim 4 is vague and indefinite because the specific hybridization conditions are not known and not recited.  
Claim 5 is vague and indefinite because the specific amino acids residues to be "deleted, substituted, inserted or added" are not known and not recited.

***Claim Rejections - 35 U.S.C. § 102***

12. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:  
A person shall be entitled to a patent unless --  
(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.  
(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
13. Claim 4 is rejected under 35 U.S.C. 102(a) as being anticipated by Asada et al. (Accession AAT08131).  
Asada et al. teach a hyperthermostable protease gene which is expected to hybridize to

Art Unit: 1652

SEQ ID NO: 2 since no specific hybridization conditions have been recited (see enclosed nucleotide to nucleotide alignment). Thus, the reference teachings anticipate the claimed invention.

14. Claim 5 is rejected under 35 U.S.C. 102(a) as being anticipated by Asada et al. (Accession AAT08131).


Asada et al. teach a hyperthermostable protease gene encoding a hyperthermostable protease consisting of an amino acid sequence in which one or more amino acid residues are deleted, substituted, inserted, or added to the amino acid sequence of SEQ ID NO: 1. (see enclosed amino acid to nucleotide alignment). Thus, the reference teachings anticipate the claimed invention.

*Conclusion*

15. No claim is allowed.

16. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L. Fronda whose telephone number is (703)305-1252. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703)308-3804. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703)308-0196.

CLF

  
PONNATHAPURACHUTAMURTHY  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600